Skip to main content
Top
Published in: Rheumatology International 7/2011

01-07-2011 | Letter to the Editor

Non-traumatic fracture of the femoral shaft in a patient taking long-term bisphosphonate therapy

Authors: Joong Kyong Ahn, Jaejoon Lee, Hoon-Suk Cha, Eun-Mi Koh

Published in: Rheumatology International | Issue 7/2011

Login to get access

Excerpt

Bisphosphonates are one of the most potent drugs in the treatment of postmenopausal osteoporosis and have demonstrated improvement in bone mineral density (BMD) and reduction in the incidence of osteoporotic fracture [1]. These drugs have also been used for the treatment of Paget’s disease and glucocorticoid-induced osteoporosis. FDA-approved bisphosphonates used for the prevention and treatment of osteoporosis include alendronate, risedronate and ibandronate [2]. Although long-term use of bisphosphonates confirms their safety, the questions regarding the potential adverse effect due to excessive inhibition of bone remodeling still remain [1, 3]. Here, we report a rare case of atypical fracture of femoral shaft in a patient taking long-term bisphosphonate therapy. …
Literature
1.
2.
go back to reference Lane NE (2008) Kelley’s Textbook of Rheumatology, 8th edn, pp 1579–1599 Lane NE (2008) Kelley’s Textbook of Rheumatology, 8th edn, pp 1579–1599
3.
go back to reference Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304–1306PubMedCrossRef Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304–1306PubMedCrossRef
4.
go back to reference Laroche M (2008) Treatment of osteoporosis: all the questions we still cannot answer. Am J Med 121:744–747PubMedCrossRef Laroche M (2008) Treatment of osteoporosis: all the questions we still cannot answer. Am J Med 121:744–747PubMedCrossRef
5.
go back to reference Visekruna M, Wilson D, McKiernan FE (2008) Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93:2948–2952PubMedCrossRef Visekruna M, Wilson D, McKiernan FE (2008) Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93:2948–2952PubMedCrossRef
6.
go back to reference Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613–620PubMedCrossRef Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613–620PubMedCrossRef
7.
go back to reference Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301PubMedCrossRef Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301PubMedCrossRef
8.
go back to reference Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095–1102PubMedCrossRef Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095–1102PubMedCrossRef
9.
go back to reference Kwek EB, Goh SK, Koh JS, Png MA, Howe TS (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224–231PubMedCrossRef Kwek EB, Goh SK, Koh JS, Png MA, Howe TS (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224–231PubMedCrossRef
10.
go back to reference Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 296:2927–2938PubMedCrossRef Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 296:2927–2938PubMedCrossRef
Metadata
Title
Non-traumatic fracture of the femoral shaft in a patient taking long-term bisphosphonate therapy
Authors
Joong Kyong Ahn
Jaejoon Lee
Hoon-Suk Cha
Eun-Mi Koh
Publication date
01-07-2011
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 7/2011
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1477-3

Other articles of this Issue 7/2011

Rheumatology International 7/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.